The Silverstein Foundation In the News

The Silverstein Foundation has been featured in national and international publications and broadcast media. Explore the thinks below to see and hear what others are saying about the Foundation and our Founder’s story.

2023 Year In Review

Last year marked our 6th year of supporting research into therapies for the treatment of Parkinson’s disease in GBA mutation carriers (GBA-PD). While we transitioned from a public charity to a private foundation in 2023, we were excited to continue our innovative work through several new initiatives.

2022 Year In Review

This year marks our 5th year of supporting research into therapies for the treatment of Parkinson’s disease in GBA mutation carriers. We are proud of our many accomplishments and collaborative relationships, which...

Prevail Therapeutics Acquired by Lilly

Acquisition will establish a gene therapy program at Lilly, anchored by Prevail’s portfolio of neuroscience assets, and will broaden Lilly’s commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease.

Prevail Announces First Patient Dosed

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN).

Aspen Neuroscience Announces $70 Million Series A Financing

Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.

The Silverstein Foundation and Q-State Biosciences Launch Chamishi Therapeutics

The Silverstein Foundation for Parkinson’s with GBA and Q-State Biosciences today announced the formation and launch of Chamishi Therapeutics, a drug discovery and development company focused on neurodegenerative diseases and other related disorders. Chamishi will initially focus on developing antisense oligonucleotide (ASO) therapies for Glucosylceramidase Beta Acid (GBA)-Parkinson’s disease.

The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA Grant Nearly $3 Million to Studies into Disease’s Most Common Known Genetic Contributor

Mutations in the GBA gene are the most common genetic risk factors for Parkinson’s, affecting about 10 percent of the more than 6 million people estimated to have the disease. The projects selected through this joint funding program aim to better understand the effect of GBA mutations – and the role of GBA more generally – and advance treatments against this target.

Press Release: Prevail Therapeutics Announces $75 Million Series A Financing

Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing.  Investors in the round included OrbiMed, Pontifax, RA Capital, EcoR1 Capital, Omega Funds, BVF Partners L.P., Boxer Capital LLC, Adage Capital Management L.P., and Alexandria Venture Investments. OrbiMed and the Silverstein Foundation for Parkinson’s with GBA incubated and provided seed funding to Prevail.

Press Release: March 8th Workshop on Accelerating Therapeutic Development in GBA-associated PD

New York, New York – March 8, 2018 – The Silverstein Foundation for Parkinson’s with GBA and the Michael J. Fox Foundation for Parkinson’s Research today held a joint workshop on accelerating therapeutic development for people with glucocerebrosidase(GBA)-associated Parkinson’s Disease.  The meeting was held at the Michael J. Fox Foundation headquarters in New York City.

CNBC: Investing in a cure

August, 2017—Wall Street investor Jonathan Silverstein has spent a career finding and funding biotech firms working on cures for rare diseases. But after learning in February he has Parkinson’s Disease, the diagnosis set him and his wife on a path to...